Kimberly Binger
University of Wisconsin-Madison
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Kimberly Binger.
Clinical Cancer Research | 2007
Howard H. Bailey; Dona Alberti; James P. Thomas; Daniel Mulkerin; Kimberly Binger; Marco M. Gottardis; Robert E. Martell; George Wilding
Purpose: To assess the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacodynamics, and antitumor activity of continuous weekly-administered paclitaxel and BMS-214662, a novel farnesyl transferase inhibitor. Experimental Design: Patients were treated every week as tolerated with i.v. paclitaxel (fixed dose, 80 mg/m2/wk) administered over 1 h followed by i.v. BMS-214662 (escalating doses, 80–245 mg/m2/wk) over 1 h starting 30 min after completion of paclitaxel. Results: Twenty-six patients received 94 courses (one course, 21 days) of study treatment. Two patients received five courses of BMS-214662 as a weekly 24-h infusion (209 mg/m2/wk). The most common toxicities were grade 1 to 2 nausea/vomiting and/or diarrhea. DLTs observed at or near the MTD (200 mg/m2/wk) were grade 4 febrile neutropenia with sepsis occurring on day 2 of course 1 (245 mg/m2/wk), reversible grade 3 to 4 serum transaminase increases on day 2, and grade 3 diarrhea (200 and 245 mg/m2/wk). Objective partial responses were observed in patients with pretreated head and neck, ovarian, and hormone-refractory prostate carcinomas, and leiomyosarcoma. The observed pharmacokinetics of paclitaxel and BMS-214662 imply no interaction between the two. Significant inhibition (>80%) of farnesyl transferase activity in peripheral mononuclear cells was observed at the end of BMS-214662 infusion. Conclusions: Pretreated patients with advanced malignancies can tolerate weekly paclitaxel and BMS-214662 at doses that achieve objective clinical benefit. Due to multiple DLTs occurring at the expanded MTD, the recommended phase 2 dose and schedule is paclitaxel (80 mg/m2 over 1 h) and BMS-214662 (160 mg/m2 over 1 h) administered weekly.
American Journal of Clinical Oncology | 2003
Glenn Liu; Howard H. Bailey; Rhoda Z. Arzoomanian; Dona Alberti; Kimberly Binger; Jennifer Volkman; Chris Feierabend; Rebecca Marnocha; George Wilding; James P. Thomas
Piritrexim is a new antifolate that has shown activity in methotrexate-resistant tumors. Gemcitabine is an antimetabolite similar in structure to cytosine arabinoside with early studies demonstrating activity in a variety of cancers. It also has apparent synergistic activity with antifolates from initial work in tumor models. Paclitaxel is an antimicrotubule agent that has a wide spectrum of activity against a variety of solid tumors. The combination of gemcitabine, paclitaxel, and piritrexim was assessed in this phase I trial. Thirty patients were enrolled. The starting doses were piritrexim 25 mg orally twice daily (days 1–4, 15–18), paclitaxel 75 mg/m2 (days 1, 15), and gemcitabine 750 mg/m2 (days 1, 15), which then was escalated in a stepwise fashion. Four patients achieved stable disease while on study, whereas one patient with a poorly differentiated neuroendocrine tumor achieved a partial response. The main toxicity was myelosuppression. The maximum tolerated dose was thought to be piritrexim 25 mg orally three times daily (days 1–4), paclitaxel 150 to 175 mg/m2 (days 1, 15), and gemcitabine 1,000 mg/m2 (days 1, 15). The combination of these new antifolates with paclitaxel and gemcitabine appears safe and should be considered for phase II trials in known responsive tumors such as transitional cell carcinomas.
Cancer Chemotherapy and Pharmacology | 2002
James P. Thomas; Kendra D. Tutsch; James F. Cleary; Howard H. Bailey; Rhoda Z. Arzoomanian; Dona Alberti; Kris Simon; Chris Feierabend; Kimberly Binger; Rebecca Marnocha; Amy Dresen; George Wilding
Cancer Chemotherapy and Pharmacology | 2003
Sherry Morgan-Meadows; Sarita Dubey; Michael N. Gould; Kendra D. Tutsch; Rebecca Marnocha; Rhoda Arzoomanin; Dona Alberti; Kimberly Binger; Chris Feierabend; Jennifer Volkman; Shawna Ellingen; Sandra Black; Marcia Pomplun; George Wilding; Howard H. Bailey
Cancer Chemotherapy and Pharmacology | 2008
Noelle K. LoConte; James P. Thomas; Dona Alberti; Jennifer Heideman; Kimberly Binger; Rebecca Marnocha; Kyle N. Utecht; Peter G. Geiger; Jens C. Eickhoff; George Wilding; Jill M. Kolesar
Cancer Chemotherapy and Pharmacology | 2001
James P. Thomas; Rhoda Z. Arzoomanian; Dona Alberti; Chris Feierabend; Kimberly Binger; Kendra D. Tutsch; Thomas H. Steele; Rebecca Marnocha; Charlotte Smith; S. Smith; John S. Macdonald; George Wilding; Howard H. Bailey
Cancer Chemotherapy and Pharmacology | 2011
Justine Yang Bruce; Jill M. Kolesar; Hans J. Hammers; Mark N. Stein; Lakeesha Carmichael; Jens C. Eickhoff; Susan Johnston; Kimberly Binger; Jennifer Heideman; Scott B. Perlman; R Jeraj; Glenn Liu
Clinical Cancer Research | 2002
Glenn Liu; Jordan Berlin; Kendra D. Tutsch; Lynn Van Ummersen; Amy Dresen; Rebecca Marnocha; Rhoda Arzomanian; Dona Alberti; Chris Feierabend; Kimberly Binger; George Wilding
Journal of Clinical Oncology | 2005
R. B. Hegeman; Daniel Mulkerin; James P. Thomas; Dona Alberti; Kimberly Binger; Rebecca Marnocha; Jill M. Kolesar; George Wilding
Cancer Chemotherapy and Pharmacology | 2018
M Scarpelli; Murtuza Rampurwala; Jens C. Eickhoff; Lakeesha Carmichael; Jennifer Heideman; Kimberly Binger; Jill M. Kolesar; Scott B. Perlman; Kim Harrow; Gary Dukart; Chris Liang; R Jeraj; Glenn Liu; Justine Yang Bruce